OasisLMS

1. Describe the epidemiology of heart failure and implement strategies for the prevention of heart failure.
2. Describe the pathophysiology of heart failure, including normal physiology and compensatory and maladaptive mechanisms.
3. Assess and track the patient with acute or advanced heart failure, using non-invasive and invasive tests and biomarkers.
4. Implement guideline-based therapy for patients with chronic heart failure, including pharmacologic agents and non-pharmacologic options, such as diet and exercise; and implantable devices.
5. Apply appropriate care strategies for patients with pulmonary hypertension, RV failure, heart failure with preserved ejection fraction, cardiorenal syndrome, peripartum and infiltrative myopathies.
6. Manage comorbidities in patients with chronic heart failure, including sleep disordered breathing, anemia, and depression.
7. Implement strategies for effective disease management of the patient with advanced heart failure, including palliative care and transition to outpatient care.
8. Describe characteristics of optimal candidates for cardiac transplantation or mechanical circulatory support.
9. Apply strategies for atrial and ventricular arrhythmia management.
10. Practice effectively in the context of health

• Patient care
• Medical knowledge
• Interpersonal and communication skills
• Professionalism
• Systems‐based

• Epidemiology and risk factors
• Pathophysiology of heart failure
• Hemodynamics and hemodynamic monitoring
• Heart failure and normal ejection fraction
• Heart failure with renal dysfunction/cardiorenal syndrome
• Diagnostic tests and procedures
• Acute decompensation of chronic heart failure
• Heart failure comorbidities
• Cardiomyopathies
• Pharmacotherapy
• Implantable devices
• Heart transplant
• Mechanical circulatory

• Models and Mechanisms of HFrEF and HFpEF - James C. Fang, MD, FHFSA
• HF Pathway - Translating Guidelines Into Clinical Practice  - Robert J. Mentz, MD, FHFSA
• Transcatheter Mitral Valve Repair and Replacement  - Nir Uriel, MD, MSc
• Diabetes & Heart Failure - Robert J. Mentz, MD, FHFSA
• Emerging Therapies: New Indications and Drugs in the Pipeline  - Theodore Berei, PharmD, MBA, BCPS, BCCP
• HFpEF: Therapeutic Options - Sumeet Mitter, MD, MSCE
• Acute HF:  Natural History & Patient Assessment - James C. Fang, MD, FHFSA
• Inotropes - What’s New? - Mahazrin B. Ginwalla, MD, MS
• Acute HF: Congestion, Cardiorenal and Diuretic Resistance - Maria Rosa Costanzo, MD
• Case Based Discussion - HF Across Lifespan (Acute and Chronic) - Moderator: Marie Galvao, MSN, ANP-BC, CHFN
  • Panel Discussants: Robert J. Mentz, MD, FHFSA ; Lisa D. Rathman, MSN, CRNP, CCRN; Theodore Berei, PharmD, MBA, BCPS, BCCP

• Pulmonary Hypertension I:  Diagnosis and Management - Jonathan D. Rich, MD, FHFSA
• Pulmonary Hypertension II:  Pharmacotherapy - Jonathan D. Rich, MD, FHFSA
• Who II PH and Right Failure  - Manreet Kanwar, MD
• Case Based Discussion -  Moderator: Sean P. Pinney, MD;
  • Panel Discussants: Jonathan D. Rich, MD, FHFSA; Linda Ordway, RN, MS, ACNP, CHFN; Robert Page II, PharmD, MSPH, BCPS, FHFSA

• Assessment of Patient with New Onset HF
  Marie Galveo, MSN, ANP-BC, CHFN; Robert Page II, PharmD, MSPH, BCPS, FHFSA; Maria Rosa Costanzo, MD
• Cardiopulmonary Exercise Stress Testing (CPET)
  Stephen Clum, PhD, MD; Mahazrin B. Ginwalla, MD, MS
• How to Set up a HF Clinic
  Sumeet Mitter, MD, MSCE; Sara Paul, DNP, FNP, FHFSA; Kathleen D. Faulkenberg, PharmD 

• Biomarker 2019 Update:  What’s Hot, What’s Not? - Mahazrin B. Ginwalla, MD, MS
• Invasive and Non-Invasive Hemodynamic Devices - Manreet Kanwar, MD 
• Remote Monitoring: Smart Phones to Telehealth - Lisa D. Rathman, MSN, CRNP, CCRN
• Sleep Disordered Breathing  - Sara Paul, DNP, FNP, FHFSA
• Q&A

• Cardiogenic Shock: Pathophysiology, Hemodynamics and Outcomes - Debbie Rinde-Hoffman, MD, FHFSA
• Percutaneous Devices and ECMO - Susan M. Joseph, MD
• Cardiac Amyloidosis - Sumeet Mitter, MD, MSCE 

• Patient Preferences vs Provider Perception - Luis H . Arroyo, MD; Linda Ordway, RN, MS, ACNP; Robert Page II, PharmD, MSPH, BCPS, FHFSA
• Patient Panel

• Impact of AFIB on HF - Sean P. Pinney, MD
• EP Device Therapy of HF: CRT, HIS  Bundle Pacing and CCM - Usman Siddiqui, MD
• Arrhythmia Management: Antiarrhythmic Drugs and VT Ablation  - Usman Siddiqui, MD
• Prevention of Sudden Cardiac Death, Wearables and Implantables  - Luis Arroyo, MD 

• How to Setup a Remote Monitoring Program - Lisa D. Rathman, MSN, CRNP, CCRN; Robert Page II, PharmD, MSPH, BCPS, FHFSA
• Having the Discussion - How to Make the Conversation Easier - Maria Rosa Costanzo, MD; Sara Paul  DNP, FNP, FHFSA
• Clinical Conundrums - Case Review - Sean P. Pinney, MD; Marie Galvao, MSN, ANP‐BC, CHFN; Kathleen D. Faulkenberg, PharmD

• Defining Advanced HF - Sean P. Pinney, MD
• Inflammatory Cardiomyopathies, Myocarditis and Sarcoidosis - Nirav Raval, MD
• Metabolic Challenges: Obesity and Anemia - Justin Vader, MD
• HF and Pregnancy - Lisa LeMond, MD
• Hypertrophic Cardiomyopathies and Screening for Sudden Cardiac Death - Nirav Rival, MD

• Cardio-Oncology - Justin Vader, MD
• Transitional Care Planning & Strategies for Keeping People Out of the Hospital - Sara Paul, DNP, FNP, FHFSA
• Pallative Care and Hospice - Lisa LeMond, MD
• Q&A

PHYSICIANS
The Heart Failure Society of America is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Heart Failure Society of America designates this live activity for a maximum of 18.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

Successful completion of this CME activity, which includes participation in the evaluation component and post-test with 75% passing score, enables the participant to earn up to 18.50 MOC points in the Maintenance of Certification (MOC) program. 

NURSES
This continuing nursing education activity was approved by the Ohio Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. (OBN-001-91)
This activity is approved for 18.50 contact hours.
Approval through 10/23/2021; ONA #22787

CRITERIA FOR SUCCESSFUL COMPLETION & CREDIT CERTIFICATES
Successful completion of this continuing education activity includes participation in the evaluation post course evaluation and post-course test with a passing score of 75%.

The following accreditors with ability to control content for this activity have no conflict of interest:
Luis H. Arroyo, MD
Theodore Berei, PharmD, MBA, BCPS, BCCP
Stephen Clum, PhD, MD
Kathleen D. Faulkenberg, PharmD
Manreet Kanwar, MD
Joseph Lawrie (Patient)
Lisa LeMond, MD
Sanwarren Nix (Patient)
Linda Ordway, RN, MS, ACNP, CHFN
Robert Page II, PharmD, MSPH, BCPS, FHFSA - Co-Chair; (Planning Committee & Presenter)
Nirav Raval, MD
Christina Redmond, MSN, ARNP (Planning Committee)
Jonathan Rich, MD, FHFSA
Debbie Rinde-Hoffman, MD, FHFSA
Justin Vader, MD
William Vanwagner (Patient)

HFSA Staff Planners
Jaime Abreu, MBA
Shauna Brown
Cynthia Miranda

The following accreditors with ability to control content for this activity have listed the below disclosures:
Maria Rosa Costanzo, MD
Consultant-Advisory Board: CHF-Solutions; Magenta Medical; Sequana; Axon Technologies

James C. Fang, MD, FHFSA
Consultant-Advisory Board: Novartis; Amgen; Capricor; Johnson & Johnson; American Heart Association; NIH; PVOMICS/CTSN

Marie Galvao, MSN, ANP‐BC, CHFN  - Co-Chair
(Planning Committee & Presenter)
Speaker Honoraria: Boston Scientific
Consultant-Advisory Board: Boston Scientific

Mahazarin Ginwalla, MD, MS
Research Grant: Amgen
Speaker-Honoraria: Zoll
Consultant-Advisory Board: Xact Labs

Susan M. Joseph, MD
Speaker-Honoraria: Abbott
Consultant-Advisory Board: Medtronic

Robert J. Mentz, MD, FHFSA
Research Grant: Amgen; AstraZeneca; Bayer; GlaxoSmithKline; American Regent; Medtronic; Merck; Novartis; Sanofi
Speaker-Honoraria: Amgen; AstraZeneca; Bayer; Innolife; Medtronic; Merck; Novartis; Sanofi; Abbott; Boston Scientific; Janssen; Vifor; Boehringer Ingelheim
Consultant-Advisory Board: Amgen; AstraZeneca; Innolife; Metronic; Merck; Novartis; Sanogi; Abbott; Vifor; Boehringer Ingelheim

Sumeet Mitter, MD, MSCE
Speaker-Honoraria: Abbott; Cowen & Co.; American College of Cardiology
Consultant-Advisory Board: AstraZeneca; Pfizer

Sara Paul, DNP, FNP, FHFSA
Consultant-Advisory Board: Abbott

Sean P. Pinney, MD - Co-Chair
(Planning Committee & Presenter)
Speaker-Honoraria: CareDx
Consultant-Advisory Board: Abbot, Inc.; CareDx; Medtronic, Inc.

Lisa D. Rathman, MSN, CRNP, CCRN
Research Grant: Abbott
Speaker-Honoraria: Abbott, Boston Scientific
Consultant-Advisory Board: Abbott, Boston Scientific, Amgen, Alnylam, Pfizer, Boehringer Ingelheim, SC Pharma

Usman Siddiqui, MD
Consultant-Advisory Board: Biosense Webster; Medtronic; Impulse Dynamics; Stereotaxis

Nir Uriel, MD, MSc
Research Grant: Abbott, Medtronic, Novartis
Consultant-Advisory Board: Leviticus, Cormetric